Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$70,000.00
The role of IL-15 and NK cells in tumor formation in a mouse model of spontaneous mammary carcinogenesis.
FY 2008-09
Summary
Breast cancer is currently the most common cancer in Canadian women. While the prognosis for women with breast cancer is improving, more research needs to be done. Our lab is focusing on the role of the innate immune system in breast tumor protection. Cancer forms frequently in the body, but usually, innate immune cells such as Natural Killer (NK) cells are able to recognize the tumor cell and kill it. These NK cells are activated by molecules such as IL-15 and ligands for Tol-like receptor (TLRs). We will be using mouse models to investigate the role of NK cells and IL-15 in breast tumor formation. We have IL-15 knockout (KO) mice that have no IL-15 and no NK cells. In contrast, we have IL-15 transgenic (TG) mice that have very high levels of IL-15 and thus NK cells. We also have a mouse model (MT mice) in which spontaneous breast tumors form within 2 to 4 months of birth. We will mate both the IL-15 KO and IL-15 Tg mice with the tumor MT mice. We predict that the absence of IL-15/NK cells will accelerate tumor formation, whereas the overexpression of IL-15/NK cells will impede tumor formation. To determine if the IL-15/NK cells are the key molecules in tumor formation, we will restore the NK cell numbers in the IL-15KO/MT tumor mice. This should decrease the rate of breast tumor formation. In contrast, we will remove the extra IL-15/NK cells in the IL-15 TG/MT tumor mice. This should facilitate tumor formation in these mice. Our last aim is to look at the ability of TLR ligands (FimH and polyI:C) to protect from breast cancer in the MT tumor model. We want to determine if treatment with these ligands will cause tumors to shrink. All of the above strategies will determine if we can use various aspects of the innate immune system to prevent tumor formation or to use as immunotherapy.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
184345
Name
Gillgrass Amy E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The role of IL-15 and NK cells in tumor formation in a mouse model of spontaneous mammary carcinogenesis.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Immunotherapy; Elisas; Flow Cytometry; Il-15; Innate Immunity; Metastasis; Mouse Models; Nk Cells
Abstract
Breast cancer is currently the most common cancer in Canadian women. While the prognosis for women with breast cancer is improving, more research needs to be done. Our lab is focusing on the role of the innate immune system in breast tumor protection. Cancer forms frequently in the body, but usually, innate immune cells such as Natural Killer (NK) cells are able to recognize the tumor cell and kill it. These NK cells are activated by molecules such as IL-15 and ligands for Tol-like receptor (TLRs). We will be using mouse models to investigate the role of NK cells and IL-15 in breast tumor formation. We have IL-15 knockout (KO) mice that have no IL-15 and no NK cells. In contrast, we have IL-15 transgenic (TG) mice that have very high levels of IL-15 and thus NK cells. We also have a mouse model (MT mice) in which spontaneous breast tumors form within 2 to 4 months of birth. We will mate both the IL-15 KO and IL-15 Tg mice with the tumor MT mice. We predict that the absence of IL-15/NK cells will accelerate tumor formation, whereas the overexpression of IL-15/NK cells will impede tumor formation. To determine if the IL-15/NK cells are the key molecules in tumor formation, we will restore the NK cell numbers in the IL-15KO/MT tumor mice. This should decrease the rate of breast tumor formation. In contrast, we will remove the extra IL-15/NK cells in the IL-15 TG/MT tumor mice. This should facilitate tumor formation in these mice. Our last aim is to look at the ability of TLR ligands (FimH and polyI:C) to protect from breast cancer in the MT tumor model. We want to determine if treatment with these ligands will cause tumors to shrink. All of the above strategies will determine if we can use various aspects of the innate immune system to prevent tumor formation or to use as immunotherapy.
Competitiondate
200810
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Gillgrass, Amy E
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $70,000~ $0~